- Home
- REVBW vs OPRA Comparison
REVBW vs OPRA Comparison
Compare REVBW & OPRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- OPRA
- Stock Information
- Founded
- REVBW N/A
- OPRA 1996
- Country
- REVBW United States
- OPRA Norway
- Employees
- REVBW 9
- OPRA N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- OPRA Computer Software: Prepackaged Software
- Sector
- REVBW Health Care
- OPRA Technology
- Exchange
- REVBW Nasdaq
- OPRA Nasdaq
- Market Cap
- REVBW N/A
- OPRA N/A
- IPO Year
- REVBW 2020
- OPRA 2018
- Fundamental
- Price
- REVBW $0.01
- OPRA $16.59
- Analyst Decision
- REVBW
- OPRA Strong Buy
- Analyst Count
- REVBW 0
- OPRA 5
- Target Price
- REVBW N/A
- OPRA $24.80
- AVG Volume (30 Days)
- REVBW N/A
- OPRA 436.2K
- Earning Date
- REVBW N/A
- OPRA 04-24-2025
- Dividend Yield
- REVBW N/A
- OPRA 4.82%
- EPS Growth
- REVBW N/A
- OPRA N/A
- EPS
- REVBW N/A
- OPRA 0.90
- Revenue
- REVBW N/A
- OPRA $480,648,000.00
- Revenue This Year
- REVBW N/A
- OPRA $20.29
- Revenue Next Year
- REVBW N/A
- OPRA $15.79
- P/E Ratio
- REVBW N/A
- OPRA $17.93
- Revenue Growth
- REVBW N/A
- OPRA 21.12
- 52 Week Low
- REVBW N/A
- OPRA $10.11
- 52 Week High
- REVBW N/A
- OPRA $22.50
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- OPRA 41.04
- Support Level
- REVBW N/A
- OPRA $15.38
- Resistance Level
- REVBW N/A
- OPRA $18.56
- Average True Range (ATR)
- REVBW 0.00
- OPRA 0.65
- MACD
- REVBW 0.00
- OPRA -0.12
- Stochastic Oscillator
- REVBW 0.00
- OPRA 38.05
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).